Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0YO4C
|
|||
| Former ID |
DIB013588
|
|||
| Drug Name |
Xilonix
|
|||
| Indication | Colorectal cancer [ICD-11: 2B91.Z] | Phase 3 | [1] | |
| Influenza virus infection [ICD-11: 1E30-1E32] | Phase 3 | [2] | ||
| Non-small-cell lung cancer [ICD-11: 2C25.Y; ICD-9: 162] | Phase 2 | [3] | ||
| Company |
Xbiotech
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT02138422) A Phase 3 Study to Evaluate Xilonix as an Anticancer Therapy in Patients With Symptomatic Colorectal Cancer. U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of Xbiotech. | |||
| REF 3 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 4 | Clinical pipeline report, company report or official report of xbiotech. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.